Parkside Advisors LLC acquired a new stake in Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,618 shares of the healthcare product maker’s stock, valued at approximately $262,000.

Several other large investors have also made changes to their positions in ABT. Vanguard Group Inc. grew its position in Abbott Laboratories by 1.6% during the third quarter. Vanguard Group Inc. now owns 139,012,321 shares of the healthcare product maker’s stock valued at $10,197,944,000 after acquiring an additional 2,208,781 shares during the period. Vanguard Group Inc grew its position in Abbott Laboratories by 1.6% during the third quarter. Vanguard Group Inc now owns 139,012,321 shares of the healthcare product maker’s stock valued at $10,197,944,000 after acquiring an additional 2,208,781 shares during the period. BlackRock Inc. grew its position in Abbott Laboratories by 0.9% during the third quarter. BlackRock Inc. now owns 117,203,489 shares of the healthcare product maker’s stock valued at $8,598,048,000 after acquiring an additional 1,053,749 shares during the period. Bank of New York Mellon Corp grew its position in Abbott Laboratories by 102,159.4% during the third quarter. Bank of New York Mellon Corp now owns 27,234,758 shares of the healthcare product maker’s stock valued at $1,997,943,000 after acquiring an additional 27,208,125 shares during the period. Finally, Morgan Stanley grew its position in Abbott Laboratories by 7.3% during the third quarter. Morgan Stanley now owns 22,766,174 shares of the healthcare product maker’s stock valued at $1,670,126,000 after acquiring an additional 1,547,898 shares during the period. 72.75% of the stock is owned by institutional investors and hedge funds.

In related news, Chairman Miles D. White sold 142,341 shares of the business’s stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $72.35, for a total value of $10,298,371.35. Following the transaction, the chairman now owns 3,459,185 shares in the company, valued at $250,272,034.75. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jared Watkin sold 65,000 shares of the business’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $71.00, for a total value of $4,615,000.00. Following the completion of the transaction, the insider now owns 128,640 shares in the company, valued at approximately $9,133,440. The disclosure for this sale can be found here. Insiders own 0.74% of the company’s stock.

ABT has been the subject of a number of research reports. Citigroup downgraded Abbott Laboratories from a “neutral” rating to a “sell” rating and lowered their price target for the company from $72.00 to $68.00 in a research report on Wednesday, January 2nd. UBS Group started coverage on Abbott Laboratories in a research note on Tuesday, November 27th. They set a “buy” rating and a $83.00 price objective on the stock. Morgan Stanley boosted their price objective on Abbott Laboratories from $70.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. Cowen boosted their price objective on Abbott Laboratories from $72.00 to $86.00 and gave the stock an “average” rating in a research note on Friday, October 5th. Finally, Zacks Investment Research cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, September 19th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $76.86.

Shares of NYSE:ABT traded up $0.25 during trading on Friday, hitting $69.33. The company’s stock had a trading volume of 4,769,924 shares, compared to its average volume of 8,115,916. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.13 and a current ratio of 1.42. Abbott Laboratories has a fifty-two week low of $55.58 and a fifty-two week high of $74.92. The stock has a market cap of $121.96 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 1.86 and a beta of 1.24.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 17th. The healthcare product maker reported $0.75 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.75. Abbott Laboratories had a return on equity of 16.05% and a net margin of 2.91%. The business had revenue of $7.66 billion for the quarter, compared to analysts’ expectations of $7.65 billion. During the same quarter in the previous year, the firm posted $0.66 earnings per share. The company’s revenue was up 12.1% compared to the same quarter last year. On average, equities research analysts predict that Abbott Laboratories will post 2.89 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be paid a $0.32 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.28. The ex-dividend date is Monday, January 14th. This represents a $1.28 annualized dividend and a dividend yield of 1.85%. Abbott Laboratories’s payout ratio is 44.80%.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2019/01/11/parkside-advisors-llc-takes-262000-position-in-abbott-laboratories-abt.html.

About Abbott Laboratories

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other.

Read More: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.